Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: The last time a CEO quote was omitted and the BOD was included????

You said:

"While the NIRC isn't a cureall, it is a key step in allowing the efforts to be focussed on generating licensing revenues rather than fighting questions from without and within."

This is something I and a few others have pointed out against those fierce BoD attacks over the last years:

As long as the USPTO has not decided on the main patents, the "product" of our company, MMP, is not ready and cannot be sold.

It would be great if the '148 and the others patents in question get re-validated soon and then at least our main revenue source should be solid "forever".

And only then the company is dependent of the upcoming BoD decisions re: CEO for PTSC and PDSG and should be held responsible in either way – let's hope they make a better choice then before (hopefully Baroni plays an important role in this decision process).

GLTA

Share
New Message
Please login to post a reply